Internal Medicine · San Diego, CA
NPI
1205031010
Since 2007
Specialty
Internal Medicine
Code 390200000X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
200 W Arbor Dr
San Diego, CA, 92103
Phone (619) 543-1849
Groups this clinician bills Medicare through
Medicare paid
-
No Medicare services published
Medicare patients
-
Drug cost, 2024
$6.9M
1,807 prescriptions
Company payments
-
None reported
Medicare prescription drug claims, 2024
In 2024, the drug Soames F Boyle prescribed most often to Medicare patients was Hydroxyurea, with 217 prescriptions and refills. In total Soames F Boyle wrote 1,807 Medicare prescriptions that cost $6.9M.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-02-04.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Hydroxyurea Generic | 217 | 496 | 59 | $7,655 |
| Acyclovir Generic | 124 | 267 | 39 | $3,167 |
| Lenalidomide Generic | 120 | 120 | 16 | $1.5M |
| Dexamethasone Generic | 119 | 134 | 36 | $1,484 |
| Prednisone Generic | 58 | 85 | 16 | $556 |
| Brukinsa Zanubrutinib | 58 | 58 | Under 11 | $664K |
| Jakafi Ruxolitinib Phosphate | 53 | 53 | Under 11 | $587K |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 50 | 114 | 20 | $445 |
| Lorazepam Generic | 46 | 46 | 39 | $246 |
| Ondansetron Hcl Generic | 44 | 44 | 22 | $344 |
| Trazodone Hcl Generic | 43 | 73 | 17 | $406 |
| Prochlorperazine Maleate Generic | 42 | 42 | 24 | $568 |
| Oxycodone Hcl Generic | 42 | 42 | 33 | $296 |
| Alvaiz Eltrombopag Choline | 39 | 39 | Under 11 | $130K |
| Calquence Acalabrutinib Maleate | 35 | 35 | Under 11 | $503K |
Brand drugs: 538 claims; generic drugs: 1,269 claims; opioid claims: 48.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Soames F Boyle were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.